Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
CARVEDILOL PHOSPHATE extended-release capsules, for oral use These highlights do not include all the information needed to use CARVEDILOL PHOSPHATE EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for CARVEDILOL PHOSPHATE EXTENDED-RELEASE CAPSULES. Initial U.S. Approval: 1995
Medication labelWhy this: Advisory · dailymed-prescription
Carvedilol phosphate extended-release capsules are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4), Clinical Studies (14.1)]. Carvedilol phosphate extended-release capsules are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies (14.2)]. Carvedilol phosphate extended-release capsules are indicated for the management of essential hypertension [see Clinical Studies (14.3, 14.4)] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions (7.2)] .
- generic_name
- carvedilol phosphate
- product_names
- Carvedilol Phosphate
- ndc
- 42291-479, 42291-479-30, 42291-480, 42291-480-30, 42291-481, 42291-481-30, 42291-482, 42291-482-30
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en